Psychiatrists' attitude to antipsychotic depot treatment in patients with first-episode schizophrenia

European Psychiatry

Volumn 26, Issue 5, 2011, Pages 297-301

  Heres, S ^a   Reichhart, T ^a   Hamann, J ^a   Mendel, R ^a   Leucht, S ^a   Kissling, W ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antipsychotic; Attitude; Depot; First episode; Psychopharmacology; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; ATTITUDE; DRUG BIOAVAILABILITY; FEMALE; FIRST EPISODE PATIENT; FIRST EPISODE SCHIZOPHRENIA; FIRST EPISODE SHCIZOPHRENIA; HUMAN; MALE; MEDICAL DECISION MAKING; MEDICAL INFORMATION; PATIENT; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; PSYCHOEDUCATION; RECURRENCE RISK; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; FEMALE; HEALTH CARE SURVEYS; HUMANS; MALE; MIDDLE AGED; PSYCHIATRY; SCHIZOPHRENIA;

EID: 79960451102     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2009.12.020     Document Type: Article

References (38)

1. Ahn J., McCombs J.S., Jung C., Croudace T.J., McDonnell D., scher-Svanum H., et al. Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program. Value Health 2008, 11:48-56.
2. Chue P., Llorca P.M., Duchesne I., Leal A., Rosillon D., Mehnert A. Hospitalization rates in patients during long-term treatment with long-acting risperidone injection. J Appl Res 2005, 5:266-274.
3. Ciudad A., Alvarez E., Bobes J., San L., Polavieja P., Gilaberte I. Remission in schizophrenia: results from a 1-year follow-up observational study. Schizophr Res 2009, 108:214-222.
4. Correll C.U., Schenk E.M. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008, 21:151-156.
5. Davis J.M., Chen N., Glick I.D. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003, 60:553-564.
6. Davis J.M., Matalon L., Watanabe M.D., Blake L., Metalon L. Depot antipsychotic drugs. Place in therapy. Drugs 1994, 47:741-773.
7. de Hert M., van W.R., Wampers M., Kane J., Van O.J., Peuskens J. Remission criteria for schizophrenia: evaluation in a large naturalistic cohort. Schizophr Res 2007, 92:68-73.
8. Dunayevich E., Sethuraman G., Enerson M., Taylor C.C., Lin D. Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes. Schizophr Res 2006, 86:300-308.
9. Eerdekens M., Van H.I., Remmerie B., Mannaert E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res 2004, 70:91-100.
10. Emsley R., Medori R., Koen L., Oosthuizen P.P., Niehaus D.J., Rabinowitz J. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol 2008, 28:210-213.
11. Emsley R, Oosthuizen P, Koen L, Niehaus D, Lex A, Medori R. Remission after a first-episode of schizophrenia: Results from a 12-month analysis of patients treated with long-acting risperidone. Poster No. 0295 presented at the IEPA 2006, Birmingham, UK, 2008.
12. Falkai P., Wobrock T., Lieberman J., Glenthoj B., Gattaz W.F., Moller H.J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry 2006, 7:5-40.
13. Gaebel W, Falkai P, Weinmann S, Wobrock T. Deutsche Gesellschaft für Psychiatrie PuNH (Hrsg) S3-Praxisleitlinien in Psychiatrie und Psychotherapie, Bd 1: Behandlungsleitlinie Schizophrenie. Steinkopff, Darmstadt, 2006.
14. Hamann J., Kolbe G., Cohen R., Leucht S., Kissling W. How do psychiatrists choose among different antipsychotics?. Eur J Clin Pharmacol 2005, 61:851-854.
15. Hamann J., Leucht S., Kissling W. Shared decision making in psychiatry. Acta Psychiatr Scand 2003, 107:403-409.
16. Helldin L., Kane J.M., Karilampi U., Norlander T., Archer T. Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders. Schizophr Res 2007, 93:160-168.
17. Hendset M., Molden E., Refsum H., Hermann M. Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone. J Clin Psychopharmacol 2009, 29:537-541.
18. Heres S., Hamann J., Kissling W., Leucht S. Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry 2006, 67:1948-1953.
19. Heres S., Hamann J., Mendel R., Wickelmaier F., Pajonk F.G., Leucht S., et al. Identifying the profile of optimal candidates for antipsychotic depot therapy. A cluster analysis. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1987-1993.
20. Heres S., Schmitz F.S., Leucht S., Pajonk F.G. The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol 2007, 22:275-282.
21. Kane J.M., Aguglia E., Altamura A.C., Ayuso Gutierrez J.L., Brunello N., Fleischhacker W.W., et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998, 8:55-66.
22. Lambert M., Schimmelmann B.G., Naber D., Schacht A., Karow A., Wagner T., et al. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry 2006, 67:1690-1697.
23. Lauriello J, Lambert T, Andersen S, Lin D, Taylor CC, McDonnell D. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008:69(5):790-9.
24. Lehman A.F., Lieberman J.A., Dixon L.B., McGlashan T.H., Miller A.L., Perkins D.O., et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004, 161:1-56.
25. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
26. Medori R, Wapenaar R, de Rosario A, Rouillon F, Gaebel W, Cordes J et al. Relapse prevention and effectiveness in schizophrenia with risperidone long-acting injectable (RLAI) versus quetiapine. Poster presented at the 116th Annual Convention of the APA, Boston 2008.
27. Mentschel C LSKJ. Depot-drugs may reduce relapse rates in schizophrenic outpatients: a meta-analysis. Presented at the 156th meeting of the American Psychiatric Association, San Francisco 2003; Abstract book, p. 71.
28. Nasrallah H.A. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 2007, 115:260-267.
29. Patel M.X., David A.S. Why aren't depot antipsychotics prescribed more often and what can be done about it?. Adv Psychiatric Treat 2005, 11:203-213.
30. Patel MX, Haddad PM, Chaudry HR, McLoughlin S, Husain N, David AS. Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. J Psychopharmacol 2009 [Epub ahead of print].
31. Patel M.X., Nikolaou V., David A.S. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychol Med 2003, 33:83-89.
32. Rummel-Kluge C., Kissling W. Psychoeducation in schizophrenia: new developments and approaches in the field. Curr Opin Psychiatry 2008, 21:168-172.
33. San L., Ciudad A., Alvarez E., Bobes J., Gilaberte I. Symptomatic remission and social/vocational functioning in outpatients with schizophrenia: prevalence and associations in a cross-sectional study. Eur Psychiatry 2007, 22:490-498.
34. Sim K., Su A., Ungvari G.S., Fujii S., Yang S.Y., Chong M.Y., et al. Depot antipsychotic use in schizophrenia: an East Asian perspective. Hum Psychopharmacol 2004, 19:103-109.
35. Simpson G.M., Mahmoud R.A., Lasser R.A., Kujawa M., Bossie C.A., Turkoz I., et al. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2006, 67:1194-1203.
36. Taylor D. Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br J Psychiatry 2009, 195:s13-s19.
37. Tiihonen J., Walhbeck K., Lonnqvist J., Klaukka T., Ioannidis J.P., Volavka J., et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006, 333:224.
38. Zygmunt A., Olfson M., Boyer C.A., Mechanic D. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 2002, 159:1653-1664.